AU2010243314C1 - Phosphotetrahydropyran compounds for the treatment of wounds and fibrotic disorders - Google Patents

Phosphotetrahydropyran compounds for the treatment of wounds and fibrotic disorders Download PDF

Info

Publication number
AU2010243314C1
AU2010243314C1 AU2010243314A AU2010243314A AU2010243314C1 AU 2010243314 C1 AU2010243314 C1 AU 2010243314C1 AU 2010243314 A AU2010243314 A AU 2010243314A AU 2010243314 A AU2010243314 A AU 2010243314A AU 2010243314 C1 AU2010243314 C1 AU 2010243314C1
Authority
AU
Australia
Prior art keywords
group
formula
alkyl
aryl
fibrosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010243314A
Other languages
English (en)
Other versions
AU2010243314B2 (en
AU2010243314A1 (en
Inventor
Ian Alexander Mcdonald
Alan D. Robertson
Diego Silva
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmaxis Ltd
Original Assignee
Pharmaxis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmaxis Ltd filed Critical Pharmaxis Ltd
Publication of AU2010243314A1 publication Critical patent/AU2010243314A1/en
Assigned to PHARMAXIS LTD reassignment PHARMAXIS LTD Amend patent request/document other than specification (104) Assignors: PHARMAXIS PTY LTD.
Application granted granted Critical
Publication of AU2010243314B2 publication Critical patent/AU2010243314B2/en
Publication of AU2010243314C1 publication Critical patent/AU2010243314C1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2010243314A 2009-04-28 2010-04-28 Phosphotetrahydropyran compounds for the treatment of wounds and fibrotic disorders Ceased AU2010243314C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17341609P 2009-04-28 2009-04-28
US61/173,416 2009-04-28
PCT/IB2010/000960 WO2010125445A1 (en) 2009-04-28 2010-04-28 Phosphotetrahydropyran compounds for the treatment of wounds and fibrotic disorders

Publications (3)

Publication Number Publication Date
AU2010243314A1 AU2010243314A1 (en) 2011-12-01
AU2010243314B2 AU2010243314B2 (en) 2015-07-02
AU2010243314C1 true AU2010243314C1 (en) 2015-11-12

Family

ID=43031758

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010243314A Ceased AU2010243314C1 (en) 2009-04-28 2010-04-28 Phosphotetrahydropyran compounds for the treatment of wounds and fibrotic disorders

Country Status (10)

Country Link
US (1) US8557783B2 (enExample)
EP (1) EP2424542A4 (enExample)
JP (1) JP2012525369A (enExample)
KR (1) KR20120049183A (enExample)
AU (1) AU2010243314C1 (enExample)
CA (1) CA2760253A1 (enExample)
IL (1) IL215990A0 (enExample)
NZ (1) NZ596419A (enExample)
SG (1) SG175816A1 (enExample)
WO (1) WO2010125445A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6366598B2 (ja) * 2012-11-15 2018-08-01 タフツ ユニバーシティー ガレクチンタンパク質阻害剤を用いて被験体の眼の血管新生または繊維症を処置し、調節し、または、予防する方法、組成物、およびキット
CA3109137A1 (en) * 2018-08-10 2020-02-13 New York Univeristy Use of igf-2 receptor agonist ligands for treatment of angelman syndrome and autism
US12491203B2 (en) 2018-08-10 2025-12-09 New York University Use of mannose 6 phosphate and modifications thereof for memory enhancement and reducing memory impairment
MX2021007376A (es) 2018-12-19 2021-09-21 Univ Leland Stanford Junior Moléculas bifuncionales para el direccionamiento lisosómico y composiciones y métodos relacionados.
CN113368106B (zh) * 2020-02-25 2023-09-29 渐宽(苏州)生物科技有限公司 艾托莫德用于防治特发性肺纤维化的药物中的用途
CN113288890B (zh) * 2021-06-21 2022-02-22 南方医科大学南方医院 N-乙酰-l-半胱氨酸在制备预防和/或治疗运动损伤的药物中的应用
WO2023288033A1 (en) 2021-07-14 2023-01-19 Lycia Therapeutics, Inc. Asgpr cell surface receptor binding compounds and conjugates

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004104015A2 (en) * 2003-05-20 2004-12-02 Pharmaxis Pty Ltd. Mannose-6-phosphonate compounds for the treatment of inflammatory diseases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ872300A0 (en) 2000-07-11 2000-08-03 Praxis Pharmaceuticals Pty Ltd Compounds and methods
FR2930943B1 (fr) 2008-05-07 2011-03-18 Centre Nat Rech Scient Nouvelles utilisations de derives de d-mannopyranose inhibiteurs de l'angiogenese
FR2930942B1 (fr) 2008-05-07 2011-03-04 Centre Nat Rech Scient Nouvelles utilisations de derives de d-mannopyranose activateurs de l'angiogenese

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004104015A2 (en) * 2003-05-20 2004-12-02 Pharmaxis Pty Ltd. Mannose-6-phosphonate compounds for the treatment of inflammatory diseases

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BAUDY, R.B. et al. "Prodrugs of Perzinfotel with Improved Oral Bioavailability" Journal of Medicinal Chemistry (12 February 2009) Vol.52 No.3 pages 771 to 778 *
CLAVEL, C. et al. "Synthesis and biological activity of M6-P and M6-P analogs on fibroblast and keratinocyte proliferation" Il Farmaco (2005) Vol.60 No.9 pages 721 to 725 *
KHANJIN, N.A. et al. "Synthesis of mannose-6-phosphate analogs: large-scale preparation of isosteric mannose-6-phosphonate via cyclic sulfate precursor" Tetrahedron Letters (2002) Vol.43 No.22 pages 4017 to 4020 *

Also Published As

Publication number Publication date
IL215990A0 (en) 2012-01-31
EP2424542A1 (en) 2012-03-07
JP2012525369A (ja) 2012-10-22
AU2010243314B2 (en) 2015-07-02
WO2010125445A1 (en) 2010-11-04
US8557783B2 (en) 2013-10-15
NZ596419A (en) 2014-01-31
SG175816A1 (en) 2011-12-29
KR20120049183A (ko) 2012-05-16
CA2760253A1 (en) 2010-11-04
AU2010243314A1 (en) 2011-12-01
US20120045455A1 (en) 2012-02-23
EP2424542A4 (en) 2012-12-19

Similar Documents

Publication Publication Date Title
AU2010243314C1 (en) Phosphotetrahydropyran compounds for the treatment of wounds and fibrotic disorders
Grisanti et al. Decorin modulates wound healing in experimental glaucoma filtration surgery: a pilot study
ES2393424T3 (es) Agente farmacéutico que contiene un agonista de PPAR-delta
JP6683686B2 (ja) チャネル調節剤
Noh et al. Heat shock protein 90 inhibitor attenuates renal fibrosis through degradation of transforming growth factor-β type II receptor
AU2023222844A1 (en) Novel compositions and therapeutic methods
KR20110132446A (ko) 키나아제 단백질 결합 억제제
KR20150115959A (ko) 안과 질환의 치료를 위한 옥실리핀 화합물
AU2018369784A1 (en) RUNX1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition
EP1140048B1 (en) Use of naaladase inhibitors for the manufacture of a medicament for the treatment of certain diseases
KR20200078425A (ko) 재조합 변형된 섬유아세포 성장 인자 및 이의 치료적 용도
US8771682B2 (en) Methods and compositions for reducing interleukin-4 or interleukin-13 signaling
KR20120018761A (ko) 섬유증을 치료하기 위한 방법 및 ｐｉ-3 키나제 억제제의 조성물
Sapitro et al. Suppression of transforming growth factor-β effects in rabbit subconjunctival fibroblasts by activin receptor-like kinase 5 inhibitor
CA2896073C (en) Stimulation and enhancement of regeneration of tissues
JP2023517693A (ja) 新規ハイドロキノン誘導体
EP2970428A1 (en) Compunds for treating neurodegenerative proteinopathies
KR20130122958A (ko) 망막의 질환을 치료하기 위한 방법
US20160113900A1 (en) Inhibitors of mitochondrial stat3 and uses thereof in modulation of mast cell exocytosis
WO2022164996A1 (en) Methods of treating ocular fibrotic pathologies
Wang et al. AGTR1 blocker attenuates activation of Tenon's capsule fibroblasts after glaucoma filtration surgery via the NF-κB signaling pathway
WO2013090991A1 (en) Tgf-beta therapy
US8283323B2 (en) Withanolide compounds as inhibitors of fibrosis and identification of molecular targets for anti-fibrotic drug development
US20250170143A1 (en) Methods of treating ocular fibrotic pathologies
KR102701383B1 (ko) 리포-하이드록삼산 유도체 및 이의 약학적 용도

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 28 JUL 2015 .

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 28 JUL 2015

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired